Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)
暂无分享,去创建一个
E. Bouza | M. Vehreschild | F. Thalhammer | S. Taori | S. Goldenberg | G. Wetherill | J. V. van Oene | Areti Georgopali